2024 Most Read Articles | Blood | American Society of Hematology Top Ten Most Read Articles in 2024 Blood is pleased to announce the following most read articles that were published in 2024. Management of ALL in adults: 2024 ELN recommendations from a European expert panel Experts from the European Leukemia Net (ELN) working group for adult acute lymphoblastic leukemia have…
Iopofosine I 131 demonstrated durable efficacy and tolerability in heavily pretreated relapsed/refractory Waldenström macroglobulinemia.
Elizabeth Buchbinder, MD, discusses the implications of the FDA’s decision to grant breakthrough therapy designation to RP1 plus nivolumab in melanoma.
Benjamin Garmezy, MD, discusses the rationale for developing zelenectide pevedotin in metastatic urothelial carcinoma.
Cilta-cel without induction therapy in high-risk smoldering myeloma marked the first study of CAR T-cell therapy in a precursor cancer setting.
Key Points. BCMA-directed CART in patients with multiple myeloma and CNS involvement is feasible without excess neurotoxicityData suggests consideration fo
Real-world treatment with momelotinib led to high transfusion independence rates among patients with JAK inhibitor–exposed and –naive myelofibrosis.
Key Points. BCMA-directed CART in patients with multiple myeloma and CNS involvement is feasible without excess neurotoxicityData suggests consideration fo
Drs Chan and Hunter discuss asciminib in first-line CML, OPTIC trial data on ponatinib dosing, mutational testing, and stem cell transplant strategies.
An abstract is unavailable.
James J. Harding, MD, details the significance of the approval of zanidatamab and how the agent could fill unmet needs in biliary tract cancers.
